Patents Assigned to Ethypharm
-
Publication number: 20060121115Abstract: The invention relates to a heat-sensitive composition in liquid form, containing: an organic hydrophobic liquid; an organogelling substance, the molecules of which can be bound to one another by low energy linkages; and a bioactive substance, which switches to organogel form upon coming into contact with a physiological fluid during the administration thereof into an animal body, in particular, a human.Type: ApplicationFiled: March 12, 2003Publication date: June 8, 2006Applicants: Ethypharm, Universite De MontrealInventors: Jean-Christophe Leroux, Anne-Claude Couffin-Hoarau
-
Patent number: 7041241Abstract: The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of at least 90 weeks, a therapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used preferably contain 5-fluorouracile of the tumor, by intratissular injection. The radiotherapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.Type: GrantFiled: March 18, 2003Date of Patent: May 9, 2006Assignee: Laboratoires des Prodiuts Ethiques EthypharmInventors: Nathalie Faisant, Jean-Pierre Benoit, Philippe Menei
-
Patent number: 6967028Abstract: The present invention provides microspheres intended to be administered by injection comprising a protein active ingredient and an agent coating the active ingredient intended to prolong its release, wherein they are free of any trace of organic solvent and they can be obtained according to a coating method involving bringing the active ingredient and the coating agent into contact, with stirring, in a supercritical fluid, said coating agent being soluble in this supercritical fluid.Type: GrantFiled: June 5, 2001Date of Patent: November 22, 2005Assignees: Mainelab, Laboratoires des Produits Ethiques EthypharmInventors: Claire Dulieu, Joël Richard, Jean-Pierre Benoit
-
Patent number: 6951657Abstract: The invention concerns coated particles based on granulated microcrystals of ibuprofen, its pharmaceutically acceptable isomers and salts, characterized in that they comprise a coating obtained in a fluidized bed apparatus with a hydroalcoholic dispersion consisting of a mixture comprising (A) 5 to 50% by weight of ethylcellulose relative to ibuprofen; (B) 10 to 60% by weight of hydroxypeopylmethylcellulose relative to the ethylcellulose; and (C) 1 to 40% by weight of silica with antistatic and permeabilizing properties relative to the ethylcellulose, the resulting coating, whereof at least one of the constituents can be used for granulating the ibuprofen microcrystals resulting in said particles, thereby masking the unpleasant taste of ibuprofen and significantly reducing its irritating effect on the throat after deglutition and substantially immediate release of ibuprofen when the particles are placed in an aqueous medium.Type: GrantFiled: November 3, 1999Date of Patent: October 4, 2005Assignee: Laboratoires des produits Ethiques Ethypharm SAInventors: Jean-Marc Zuccarelli, Charles André Chauveau, Gilles DeMichelis, Karine Jean
-
Publication number: 20050214378Abstract: The present invention relates to stealth lipid nanocapsules comprising an essentially lipid core which is liquid or semi-liquid at ambient temperature, and an outer lipid envelope comprising at least one hydrophilic surfactant which is lipidic in nature, at least one lipophilic surfactant which is lipidic in nature and at least one amphiphilic derivative of poly(ethylene glycol), the molar mass of the poly(ethylene glycol) component of which is greater than or equal to 1000 g/mol, preferably greater than or equal to 2000 g/mol, to the methods for the preparation thereof and to the use thereof as a carrier for active principle(s).Type: ApplicationFiled: June 11, 2003Publication date: September 29, 2005Applicant: ETHYPHARMInventors: Didier Hoarau, Pascal Delmas, Jean-Christophe Delmas
-
Publication number: 20050152976Abstract: The invention concerns coated particles with prolonged release, a method for preparing same and multiparticulate tablets comprising said coated particles.Type: ApplicationFiled: April 23, 2003Publication date: July 14, 2005Applicant: ETHYPHARMInventors: Phillippe Chenevier, Dominique Marechal
-
Patent number: 6803052Abstract: The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of least 90 weeks, a thereapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used prefereably contain 5-fluorouracile of the tumor, by intratissular injection. The radiothereapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.Type: GrantFiled: November 16, 2001Date of Patent: October 12, 2004Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Nathalie Faisant, Jean-Pierre Benoit, Philippe Menei
-
Patent number: 6794411Abstract: The invention relates to a drinkable ibuprofen solution wherein the soluble fraction of the active ingredient contained therein is less than 10% by weight in relation to the weight of the suspension.Type: GrantFiled: November 6, 2001Date of Patent: September 21, 2004Assignee: Laboratoire des Produits Ethiques EthypharmInventors: Christophe Lebon, Emmanuel Guerin, Pascal Suplie
-
Patent number: 6770298Abstract: The invention concerns a device for producing granules, in particular pharmaceutical granules, comprising a drum (4) with peripheral apertures (25) and a member (30) feeding the drum with coating or fixing substance. The drum (4) comprises mutually parallel sections (22) defining between them the apertures (25).Type: GrantFiled: August 9, 2000Date of Patent: August 3, 2004Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Patrice Debregeas, Gérard Leduc, Pascal Oury, Patrice Romain
-
Publication number: 20040076683Abstract: The present invention relates to stealth lipid nanocapsules consisting of an essentially lipid core which is liquid or semi-liquid at ambient temperature, and an outer lipid envelope comprising at least one hydrophilic surfactant which is lipidic in nature, at least one lipophilic surfactant which is lipidic in nature and at least one amphiphilic derivative of poly(ethylene glycol), the molar mass of the poly(ethylene glycol) component of which is greater than or equal to 1 000 g/mol, preferably greater than or equal to 2 000 g/mol, to the methods for the preparation thereof and to the use thereof as a carrier for active principle(s).Type: ApplicationFiled: June 11, 2003Publication date: April 22, 2004Applicant: ETHYPHARMInventors: Didier Hoarau, Pascal Delmas, Jean-Christophe Leroux
-
Patent number: 6723348Abstract: The present invention concerns orodispersible tablets, which are able to disintegrate in the buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 seconds, preferably in less than 40 seconds, containing fexofenadine in the form of coated granules, and a mixture of excipients comprising at least one disintegrating agent, a soluble diluent agent, a lubricant and optionally a swelling agent, a permeabilizing agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of said orodispersible tablets in the treatment of seasonal allergic rhinitis.Type: GrantFiled: November 16, 2001Date of Patent: April 20, 2004Assignee: EthypharmInventors: Amina Faham, Dominique Marechal, Philippe Chenevier
-
Patent number: 6660382Abstract: The invention concerns a method for making coated granules with masked taste and instant release of the active principle which consists in: first, mixing the constituents of a powder comprising at least the active principle and a granular disintegrating agent; then, granulating the resulting powder, in the presence of a mixture of carriers comprising at least a binding agent capable of binding the particles together to obtain grains; coating the grains formed by spraying a suspension comprising at least a coating agent and a membrane disintegrating agent; finally drying the resulting coated granules.Type: GrantFiled: January 8, 2002Date of Patent: December 9, 2003Assignee: EthypharmInventors: Noureddine Nouri, Jean-Marc Zuccarelli, Charles Chauveau, Etienne Bruna
-
Patent number: 6649186Abstract: Disclosed here are effervescent granules having a controllable rate of effervescence. In some embodiments, the such granules comprise an acidic agent, an alkaline agent, a pharmacologically active agent, hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process. The present invention also provides a thermal heat process for preparing a pharmacologically active agent containing effervescent granule. In certain aspects, the granules contain pharmacologically active agents such as narcotics, antidiarrheal agents, antiviral agents, anxiolytic agents, a cholesterol lowering agent, an alpha adrenergic blocking agent, a phenanthrene derivative. By way of example, some of the narcotics that may be included in the granules and in the process of preparing the granules include, by way of example: phenanthrene derivatives (e.g., morphine sulfate), and morphine derivatives (e.g.Type: GrantFiled: April 20, 2000Date of Patent: November 18, 2003Assignee: EthypharmInventors: Joseph R. Robinson, James William McGinity, Pascal Delmas
-
Publication number: 20030175356Abstract: The invention relate to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from, or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of least 90 weeks, a therapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres use preferably contain 5-fluorouracile coated with poly(d-l-lactic acid-co-glycolic acid). The microspheres are implanted in the walls of the operation site following the exeresis of the tumor, by intratissular injection. The radiotherapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.Type: ApplicationFiled: March 18, 2003Publication date: September 18, 2003Applicant: Laboratoires Des Produits Ethiques EthypharmInventors: Nathalie Faisant, Jean-Pierre Benoit, Philippe Menei
-
Patent number: 6613361Abstract: The invention concerns ketoprofen microgranules with prolonged release each consisting of an active core containing ketoprofen coated with a polymeric film enabling prolonged release of the active principle and containing acrylic polymer coatings in a volume proportion substantially equal to 90/10.Type: GrantFiled: November 15, 2001Date of Patent: September 2, 2003Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Christophe Lebon, Dominique Marechal, Pascal Suplie
-
Publication number: 20030129244Abstract: The present invention relates to a novel oral immediate-release morphine sulfate formulation in the form of microgranules.Type: ApplicationFiled: September 30, 2002Publication date: July 10, 2003Applicant: Laboratoires Des Produits Ethiques EthypharmInventors: Patrice Debregeas, Gerard Leduc, Pascal Oury, Pascal Suplie
-
Patent number: 6551621Abstract: The invention concerns omeprazole microgranules each comprising an active layer containing the active principle, and an outer gastroprotecting layer containing a gastroprotecting agent, characterized in that the omeprazole is combined with at least a hydrophobic substance.Type: GrantFiled: October 13, 2000Date of Patent: April 22, 2003Assignee: EthypharmInventors: Patrice Debregeas, Gérard Leduc, Pascal Oury, Pascal Suplie
-
Publication number: 20030017210Abstract: The invention concerns an oral formulation of cisplatin, in the form of controlled-release microgranules, and its method of formulation by grossing in an aqueous medium. The invention also concerns a pharmaceutical preparation containing controlled-release cisplatin microgranules, optionally combined with an anticancer agent, to be used in anticancer therapy. The invention further provides a use for these microgranules for making orally administered medicaments for polychemotherapy or in combination with radiotherapy.Type: ApplicationFiled: July 25, 2002Publication date: January 23, 2003Applicant: LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARMInventors: Patrice Debregeas, Gerard Leduc, Pascal Oury, Pascal Suplie
-
Publication number: 20020182253Abstract: Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).Type: ApplicationFiled: December 3, 2001Publication date: December 5, 2002Applicant: LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARMInventors: Patrice Debregeas, Gerard Leduc, Pascal Oury, Pascal Suplie
-
Patent number: 6488961Abstract: Disclosed here are effervescent granules having a controllable rate of effervescence. In some embodiments, the such granules comprise an acidic agent, an alkaline agent, a pharmacologically active agent, hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process. The present invention also provides a thermal heat process for preparing a pharmacologically active agent containing effervescent granule. In certain aspects, the granules contain pharmacologically active agents such as narcotics, antidiarrheal agents, antiviral agents, anxiolytic agents, a cholesterol lowering agent, an alpha adrenergic blocking agent, a phenanthrene derivative. By way of example, some of the narcotics that may be included in the granules and in the process of preparing the granules include, by way of example: phenanthrene derivatives (e.g., morphine sulfate), and morphine derivatives (e.g.Type: GrantFiled: December 21, 1999Date of Patent: December 3, 2002Assignee: Ethypharm, Inc.Inventors: Joseph R Robinson, James W. McGinity